1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. がんタイプ別スニペット
3.2. 治療法別
3.3. エンドユーザー別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 白血病の有病率の増加
4.1.2. 阻害要因
4.1.2.1. 治療に伴う高コスト
4.1.2.2. 厳しい規制要件
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. アンメット・ニーズ
5.6. PESTEL分析
5.7. 特許分析
5.8. SWOT分析
6. がんタイプ別
6.1. はじめに
6.1.1. 市場規模分析および前年比成長率分析（%）、がんタイプ別
6.1.2. 市場魅力度指数、がんタイプ別
6.2. 慢性骨髄性白血病
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. 急性リンパ性白血病
6.4. 急性骨髄性白血病
6.5. 慢性リンパ性白血病
6.6. その他
7. 治療法別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（%）、治療法別
7.1.2. 市場魅力度指数（治療法別
7.2. 標的療法
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 化学療法
7.4. 免疫療法
7.5. その他
8. エンドユーザー別
8.1. 導入
8.1.1. 市場規模分析および前年比成長率分析(%), エンドユーザー別
8.1.2. 市場魅力度指数、エンドユーザー別
8.2. 病院*市場
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 専門クリニック
8.4. 在宅医療
8.5. その他
9. 競争環境
9.1. 競争シナリオ
9.2. 市場ポジショニング／シェア分析
9.3. M&A分析
10. 企業プロフィール
10.1. Hoffmann-La Roche Ltd*
10.1.1. 会社概要
10.1.2. 製品ポートフォリオと内容
10.1.3. 財務概要
10.1.4. 主な展開
10.2. GlaxoSmithKline Pharmaceuticals Limited
10.3. Novartis AG
10.4. Bristol-Myers Squibb
10.5. Sun Pharmaceutical Industries Ltd
10.6. Dr.Reddy’s Laboratories Ltd
10.7. Aurobindo Pharma
10.8. Lupin
10.9. Clavis Pharma
10.10. Pfizer Inc. (*リストは除く)
11. 付録
11.1. 会社概要とサービス
11.2. お問い合わせ
The Asia Pacific leukemia therapeutics market reached US$ 340 million in 2023 and is expected to reach US$ 567.18 million by 2031, growing at a CAGR of 6.7% during the forecast period 2024-2031.
Leukemia is a blood cancer that occurs when the bone marrow produces abnormal white blood cells, also called blasts or leukemia cells. These abnormal cells can't fight infections and prevent the bone marrow from producing healthy red blood cells and platelets. Leukemia can spread to the lymph nodes, bloodstream, brain, spinal cord, and other parts of the body. If it spreads to the brain, symptoms may include headaches, seizures, balance problems, or vision problems.
If it spreads to the lymph nodes in the chest, symptoms may include breathing problems and chest pain. For the treatment of lymphoma various therapies such as targeted therapy, chemotherapy, immunotherapy, CAR T cell therapy, stem cell transplantation, and radiation therapy are used depending upon the type of leukemia and condition of the leukemia.
Market Dynamics: Drivers
Increasing prevalence of leukemia
The demand for the leukemia therapeutics market is driven by multiple factors. For instance, according to the International Agency for Research on Cancer, in 2022 more than 70,000 people lost their lives due to blood cancer in India the report also states that the country is currently seeing a surge in the number of blood cancer cases getting diagnosed which tolls at a whopping 1,20,000 in contrast to the previous report which showed an incidence rate of 1,00,000 where out of the total cases 30,000 are those seen in children.
Over 70% of the patients diagnosed with blood cancer or blood disorder in India are unable to find a match within their families and urgently need a matching unrelated donor. Moreover, according to the Leukaemia Foundation, blood cancer is one of the highest causes of cancer death in Australia, it is expected that 19,403 Australians will be newly diagnosed with blood cancers such as leukemia, lymphoma, and myeloma. This is equivalent to 53 people per day or one person every 27 minutes. The incidence of blood cancer continues to grow. The incidence of blood cancer has increased by 47% in the past 10 years. Around 135,000 people are living with a blood cancer or blood disorder in Australia. By 2035, more than 275,000 Australians are expected to be living with a blood cancer or blood disorder.
Restraints
Factors such as high costs associated with the treatment and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. For instance, according to the National Institute of Health, the cumulative drug cost for 1 year of alemtuzumab which is used in the treatment of chronic leukemia, is US$ 70,000. Higher costs of drugs which affect the drug affordability of many people are one of the aspects that acts as a restraint to the Asia Pacific leukemia therapeutics market.
Market Segment Analysis
The Asia Pacific leukemia therapeutics market is segmented based on cancer type, therapy, end-user, and region.
The targeted therapy accounted for approximately 56.5% of the Asia Pacific leukemia therapeutics market share.
The targeted therapy segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for clinical trials would drive this market.
Targeted therapy drugs are the first line of treatment for certain types of leukemia. These medicines find and target specific proteins or changes in cells that cause leukemia. Unlike chemotherapy (which affects healthy and diseased cells), targeted therapy focuses only on the cell changes that cause the cancer. The drugs cause minimal, if any, damage to healthy cells. There are different types of targeted therapy drugs for leukemia. The lab-made drugs can find specific substances in leukemia cells, such as proteins or genetic (DNA) changes. The drugs then damage or destroy the diseased cells.
For instance, in October 2023, India’s counterpart to the US Food and Drug Administration, the Central Drugs Standard Control Organization, made NexCAR19 India’s first approved CAR-T cell therapy. ImmunoACT, a spin-off company of IIT Bombay, funded the trial and will be manufacturing actalycabtagene autoleucel and bringing it to market.
Market Segmentation
By Cancer Type
Chronic Myeloid Leukemia
Acute Lymphocytic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Others
By Therapy
Targeted Therapy
Bosutinib
Venetoclax
Chemotherapy
Rituximab
Dasatinib
Immunotherapy
Ofatumumab
Brexucabtagene autoleucel
Others
By End-User
Hospitals and Clinics
Cancer Centers
Ambulatory Surgical Centers
Others
Competitive Landscape
The major players in the Asia Pacific leukemia therapeutics market include Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis AG, Bristol-Myers Squibb, Sun Pharmaceutical Industries Ltd., Dr.Reddy’s Laboratories Ltd., Aurobindo Pharma, Lupin, Clavis Pharma, and Pfizer Inc. among others.
Key Developments
In July 2024, Alembic Pharmaceuticals Limited announced that it had received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bosutinib Tablets, 100 mg and 500 mg. Bosutinib tablets are indicated for the treatment of a certain type of leukemia called Philadelphia chromosome-positive chronic myelogenous leukemia.
In February 2024, the U.S. Food and Drug Administration approved a bi-weekly dose of Johnson & Johnson's blood cancer therapy Tecvayli. The approval allows the therapy to be used in a reduced dosing of 1.5 milligrams per kilogram every two weeks, in patients who have achieved and maintained a complete response or better for a minimum of six months.
Why Purchase the Report?
To visualize the Asia Pacific leukemia therapeutics
Market Segmentation based on cancer type, therapy, and end-user, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of Asia Pacific leukemia therapeutics market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The Asia Pacific leukemia therapeutics market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Cancer Type
3.2. Snippet by Therapy
3.3. Snippet by End-User
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Leukemia
4.1.2. Restraints
4.1.2.1. High Cost Associated with the Treatment
4.1.2.2. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Cancer Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Chronic Myeloid Leukemia *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Acute Lymphocytic Leukemia
6.4. Acute Myeloid Leukemia
6.5. Chronic Lymphocytic Leukemia
6.6. Others
7. By Therapy
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.1.2. Market Attractiveness Index, By Therapy
7.2. Targeted Therapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Chemotherapy
7.4. Immunotherapy
7.5. Others
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Homecare
8.5. Others
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. Hoffmann-La Roche Ltd*
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. GlaxoSmithKline Pharmaceuticals Limited
10.3. Novartis AG
10.4. Bristol-Myers Squibb
10.5. Sun Pharmaceutical Industries Ltd
10.6. Dr.Reddy’s Laboratories Ltd
10.7. Aurobindo Pharma
10.8. Lupin
10.9. Clavis Pharma
10.10. Pfizer Inc. (*LIST NOT EXHAUSTIVE)
11. Appendix
11.1. About Us and Services
11.2. Contact Us
❖ 世界の白血病治療薬市場に関するよくある質問(FAQ) ❖
・白血病治療薬の世界市場規模は？
→DataM Intelligence社は2023年の白血病治療薬の世界市場規模を3億4,000万米ドルと推定しています。
・白血病治療薬の世界市場予測は？
→DataM Intelligence社は2031年の白血病治療薬の世界市場規模を5億6,718万米ドルと予測しています。
・白血病治療薬市場の成長率は？
→DataM Intelligence社は白血病治療薬の世界市場が2024年～2031年に年平均6.7%成長すると予測しています。
・世界の白血病治療薬市場における主要企業は？
→DataM Intelligence社は「Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis AG, Bristol-Myers Squibb, Sun Pharmaceutical Industries Ltd., Dr.Reddy’s Laboratories Ltd., Aurobindo Pharma, Lupin, Clavis Pharma, and Pfizer Inc. など ...」をグローバル白血病治療薬市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
